Company: VRCA
Filing Date: 2025-12-15
Form Type: S-3
Source: 0001193125-25-319225
Chunk: 11

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-15
Form: S-3
Chunk 11
---
     |                        |     6,770 |     | *     |
| Entities affiliated with Caligan                
 Partners LP(9)                                  |     |               |  6,503,054 |     |              | 5,157,798 |     |                        | 1,345,256 |     | 8.2%  |
| Armistice Capital, LLC(10)                      |     |               |  2,657,646 |     |              | 1,473,656 |     |                        | 1,200,990 |     | 7.3%  |
| Affinity Healthcare Fund, LP(11)                |     |               |    884,172 |     |              |   884,172 |     |                        |         — |     | —     |
| Velan Capital Master Fund LP(12)                |     |               |    589,448 |     |              |   589,448 |     |                        |         — |     | —     |
| Stonepine Capital, LP(13)                       |     |               |    442,086 |     |              |   442,086 |     |                        |         — |     | —     |
| Entities affiliated with DAFNA Lifescience L.P. 
 (14)                                            |     |               |    294,723 |     |              |   294,723 |     |                        |         — |     | —     |
| Kalehua Capital Partners LP(15)                 |     |               |    294,723 |     |              |   294,723 |     |                        |         — |     | —     |
| Parallax Biomedical Fund LP(16)                 |     |               |     58,943 |     |              |    58,943 |     |                        |         — |     | —     |

7

| * | Represents beneficial ownership of less than 1% |

| (1) | Represents all of the shares of our common stock that the selling stockholders may offer and sell from time to 
 time under this prospectus without giving effect to the beneficial ownership limitation in the Warrants.       |

| (2) | Assumes each selling stockholder sells the maximum number of Resale Shares possible in this offering. |

| (3) | “Beneficial Ownership Prior to this Offering” consists of (a) 1,375,380 shares of our common stock